GURUFOCUS.COM » STOCK LIST » USA » NYSE » Biohaven Ltd (NYSE:BHVN) » Definitions » Total Current Assets
Switch to:

Biohaven (NYSE:BHVN) Total Current Assets

: $80.55 Mil (As of Sep. 2022)
View and export this data going back to 2022. Start your Free Trial

Total current assets includes Cash And Cash Equivalents, Accounts Receivable, Total Inventories, and Other Current Assets. Biohaven's total current assets for the quarter that ended in Sep. 2022 was $80.55 Mil.


Biohaven Total Current Assets Historical Data

The historical data trend for Biohaven's Total Current Assets can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Biohaven Annual Data
Trend Dec20 Dec21
Total Current Assets
89.76 94.82

Biohaven Quarterly Data
Dec20 Jun21 Sep21 Dec21 Jun22 Sep22
Total Current Assets Premium Member Only - - 94.82 281.34 80.55

Biohaven Total Current Assets Calculation

Total Current Assets are the asset that can be converted to cash or used to pay current liabilities within 12 months.

Biohaven's Total Current Assets for the fiscal year that ended in Dec. 2021 is calculated as

Biohaven's Total Current Assets for the quarter that ended in Sep. 2022 is calculated as

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Total Current Assets is linked to the Current Ratio, which is the result of dividing total current assets by total current liabilities. It is frequently used as an indicator of a company's liquidity, its ability to meet short-term obligations.

Total Current Assets is also linked to Working Capital, Net working capital is calculated as Total Current Assets minus Total Current Liabilities.


Biohaven  (NYSE:BHVN) Total Current Assets Explanation

In Ben Graham's calculation of liquidation value, inventory is only considered worth half of its book value, and accounts receivable is considered worth 75% of its value. Therefore the liquidation value is lower than calculated from total current assets.

Biohaven's Liquidation Value for the quarter that ended in Sep. 2022 is

Liquidation value
= Cash And Cash Equivalents-Total Liabilities+(0.75 * Accounts Receivable)+(0.5 * Total Inventories)
=50.668-35.43+0.75 * 0+0.5 * 0
=15.24

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Biohaven Total Current Assets Related Terms

Thank you for viewing the detailed overview of Biohaven's Total Current Assets provided by GuruFocus.com. Please click on the following links to see related term pages.


Biohaven (NYSE:BHVN) Business Description

Biohaven logo
Comparable Companies
Traded in Other Exchanges
N/A
Address
Website
Biohaven Ltd is a commercial-stage biopharmaceutical company with a portfolio of innovative therapies to improve the lives of patients with debilitating neurological and neuropsychiatric diseases, including rare disorders. Biohaven's Neuroinnovation portfolio includes FDA-approved Nurtec ODT (rimegepant) for the acute and preventive treatment of migraine (EMA-approved as Vydura (rimegepant) for the acute treatment of migraine with or without aura, and prophylaxis of episodic migraine.
Executives
Robert J Hugin director C/O THE MEDICINES CO 8 CAMPUS DR PARSIPPANY NJ 07054
Michael Thomas Heffernan director C/O CORNERSTONE THERAPEUTICS INC. 1255 CRESCENT GREEN DRIVE, SUITE 250 CARY NC 27518
Julia P Gregory director 8800 TECHNOLOGY FOREST PLACE THE WOODLANDS TX 77381
Gregory Bailey director 4 A CHESHAM STREET LONDON X0 SW1X8DT
Kimberly Gentile officer: SVP, Clinical Operations C/O BIOHAVEN PHARMACEUTICAL HOLDING COMP 234 CHURCH STREET NEW HAVEN CT 06510
John W Childs director 111 HUNTINGTON AVENUE SUITE 2900 BOSTON MA 02199
Vlad Coric director, officer: Chief Executive Officer C/O BIOHAVEN PHARMACEUTICAL HOLDING COMP 234 CHURCH STREET NEW HAVEN CT 06510
Irina Antonijevic director 215 CHURCH STREET NEW HAVEN CT 06510
Matthew Buten officer: Chief Financial Officer 215 CHURCH STREET NEW HAVEN CT 06510
Kishan Mehta director 540 WEST 49TH STREET UNIT# PH1N NEW YORK NY 10019
Biohaven Pharmaceutical Holding Co Ltd. 10 percent owner 215 CHURCH STREET NEW HAVEN CT 06510
Bruce Car officer: Chief Scientific Officer AGIOS PHARMACEUTICALS, INC. 88 SIDNEY STREET CAMBRIDGE MA 02139

Biohaven (NYSE:BHVN) Headlines

Other Sources

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
premium membership